- cafead   Dec 11, 2023 at 10:32: AM
via The week after Novartis secured a foothold in the paroxysmal nocturnal hemoglobinuria (PNH) market, AstraZeneca has released new data from its own attempt to find fresh ways of tackling this rare blood disease.
article source
article source